ONDINE BIOMEDICAL INC. (OBI) — Audited results for the year ended 31 December 2024

Investor webinar replay

Replay transcript excerpt

Afternoon, and welcome to the ONDINE BIOMEDICAL Full Year Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to president and chief technology officer, Nicholas Lobel. Good afternoon to you. Good afternoon. Thank you, Alex. Hello to everyone. Welcome to ONDINE's full year twenty twenty four results presentation. My name is Nick Lobel, ONDINE's president and chief technology officer. We'll go through this presentation, which is also now available on our website, and take questions afterwards. This presentation provides general information. It's not intended to be comprehensive. Please review the company's annual report available today for further information. 2024 was a transformative year for ONDINE. We'll talk about our robust commercial expansion, our pivotal phase three study, which launched at the end of the year with HCA Healthcare. Our strategic distribution partnership with Mundelec Healthcare of Sweden, our leading med tech company specializing in wound care and surgical procedures. We'll touch on the launch of our high volume, high margin illuminator system driving the Steriwave revenue growth, and, of course, the successful $21,700,000 financial raise of 2024. Just in respect of key metrics, note that revenue grew 7...